Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) LT-Debt-to-Total-Asset : 0.04 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Shijiazhuang Yiling Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shijiazhuang Yiling Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.04.

Shijiazhuang Yiling Pharmaceutical Co's long-term debt to total assets ratio increased from Mar. 2023 (0.01) to Mar. 2024 (0.04). It may suggest that Shijiazhuang Yiling Pharmaceutical Co is progressively becoming more dependent on debt to grow their business.

Shijiazhuang Yiling Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shijiazhuang Yiling Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Shijiazhuang Yiling Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.01

0.04

Shijiazhuang Yiling Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.02	0.04	0.04	0.04

Shijiazhuang Yiling Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Shijiazhuang Yiling Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	612.114	/	16979.327
	=	0.04

Shijiazhuang Yiling Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	613.559	/	17128.471
	=	0.04

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shijiazhuang Yiling Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No. 7 Tianfu street, Biology and medicine industrial base, Huangcun town, Daxing district, Beijing, CHN

Website

http://www.yiling.cn/

Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company engages in the pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes and related complications. Its products include innovative drug series, chemical drugs, Chinese medicine series, and health products.

Executives

Zhang Qiu Lian	Directors, executives
Han Yue Zhi	Executives
Zhao Shao Hua	Executives
Wang Wei	Executives
Gao Xue Dong	Supervisors
Wu Yi Ling	Director
Gao Xiu Qiang	Executives
Wu Xiang Jun	Directors, executives
Guo Shuang Geng	Director
Wang Hua	Securities Affairs Representative
Dai Feng Xiang	Directors, executives
Liu Gen Wu	Supervisors
Wang Wei Ping	Directors, executives
Xu Wei Dong	Director
Wu Rui	Directors, executives

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Headlines

No Headlines